Arkolith/Insider Trading/SNDX/Form 4

Metzger Michael A

Chief Executive Officer, DirectorSyndax Pharmaceuticals Inc (SNDX) · full profile →Form 4 · filed Feb 6, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$153K
Net Open-Market Flow
-$153K
Transactions
4
3 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 6, 2026Sell(S)7K$20.62$153K509K
Feb 4, 2026Grant(A)73K—$0372K
Feb 4, 2026Grant(A)145K—$0516K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 4, 2026Grant(A)440K$20.43$9.0M440K

Transaction Codes

S
Open-market sale
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-041500) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML